Clayton has been with Freeman Technology since 2008 in a role that has encompassed both sales and applications support. As operations manager he will be responsible for all the day-to-day activities of the company, including overall management of the administration, production, r&d, sales and customer support teams.
In expanding the management team Tim Freeman, director of operations, anticipates further growth and greater opportunity to contribute expertise to the powder processing industries.
‘We want to deliver the best possible technical and applications support to our customers at all times and part of Jamie’s new role will be to ensure that every aspect of our operation runs efficiently,’ he said.
Freeman Technology appoints operations manager
Jamie Clayton takes responsibility for day-to-day activities
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Regulatory
NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case
The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach